Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment save search
INVO Bioscience Eyes +20 U.S. Cities To Expand Rollout Of Advanced Infertility Treatment 'INVO Centers'
Published: 2022-02-09 (Crawled : 13:30) - biospace.com/
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
|
| O: 0.92%
H: 3.96%
C: 1.22%
treatment eye yes bioscience
New Birmingham INVO Center Offers Families an Affordable Advanced Fertility Treatment Solution to Help Combat Rising Costs
Published: 2022-03-10 (Crawled : 14:00) - invobioscience.com
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
|
| O: -9.94%
H: 4.11%
C: 0.0%
treatment ford
TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Published: 2022-08-08 (Crawled : 13:00) - biospace.com/
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
|
| O: -2.17%
H: 5.56%
C: 5.56%
yh001 treatment antibody application submission
TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS
Published: 2022-09-14 (Crawled : 14:20) - biospace.com/
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
|
| O: 4.21%
H: 1.52%
C: -4.04%
treatment fda designation soft tissue fast track designation
TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Published: 2022-08-29 (Crawled : 12:20) - globenewswire.com
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
|
| O: 6.97%
H: 0.93%
C: -7.44%
yh001 treatment antibody approval
Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia
Published: 2024-02-20 (Crawled : 00:00) - biospace.com/
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
|
| O: -2.57%
H: 4.4%
C: 2.25%
fda treatment designation leukemia
KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
Published: 2022-08-05 (Crawled : 13:00) - prnewswire.com
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
|
| O: 37.46%
H: 4.92%
C: -23.77%
treatment therapeutics paxalisib study train brain metastases
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
Published: 2023-07-06 (Crawled : 11:00) - prnewswire.com
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
|
| O: 7.69%
H: 1.59%
C: -15.08%
fda paxalisib treatment designation tumor therapy fast track designation
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera
Published: 2022-10-21 (Crawled : 23:00) - biospace.com/
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
|
| O: 1.89%
H: 1.95%
C: 1.27%
vpo-227 treatment pharmaceuticals designation drug candidate granted
Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety
Published: 2022-12-02 (Crawled : 12:20) - biospace.com/
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
|
| O: -0.55%
H: 0.64%
C: 0.09%
vqw-765 treatment pharmaceuticals results study
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tra...
Published: 2022-12-02 (Crawled : 13:00) - biospace.com/
WDH | $1.24 2.48% -0.81% 220K
|
Finance and Insurance
|
| O: -3.09%
H: 6.37%
C: 2.55%
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
|
| O: -0.55%
H: 0.64%
C: 0.09%
URGN | $14.24 -1.73% -1.54% 190K
|
Health Technology
|
| O: -1.49%
H: 3.84%
C: -2.44%
SNDX | $20.74 -2.54% -2.55% 1.8M
|
Health Technology
|
| O: -0.16%
H: 1.12%
C: 0.32%
GTHX | News | $4.28 4.9% 4.67% 690K
|
Health Technology
|
| O: -2.22%
H: 9.27%
C: 7.69%
ACET | $2.26 3.2% 3.1% 760K
|
Health Technology
|
| O: -1.13%
H: 5.01%
C: 4.84%
jelmyto treatment trial response
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
Published: 2023-06-02 (Crawled : 02:00) - prnewswire.com
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
|
| O: 0.85%
H: 2.18%
C: 1.85%
vca-894 drug candidate granted treatment pharmaceuticals designation
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
Published: 2024-01-23 (Crawled : 15:30) - biospace.com/
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
|
| O: 2.11%
H: 1.03%
C: -4.13%
vca-894 fda drug candidate approval treatment pharmaceuticals
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
Published: 2024-01-31 (Crawled : 14:30) - biospace.com/
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
|
| O: 1.37%
H: 1.35%
C: -2.7%
vtr-297 fda drug candidate approval treatment pharmaceuticals antifungal
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
Published: 2023-12-04 (Crawled : 23:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
|
| O: 2.08%
H: 1.53%
C: 0.76%
drug food treatment pharmaceuticals application
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
Published: 2024-03-06 (Crawled : 12:00) - prnewswire.com
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: -4.4%
hetlioz fda update treatment pharmaceuticals
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Published: 2024-04-02 (Crawled : 23:00) - biospace.com/
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
|
| O: -2.43%
H: 0.0%
C: -2.74%
fanapt fda approval treatment
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
Published: 2022-11-15 (Crawled : 18:00) - globenewswire.com
ATNF | $1.91 29.05% 22.51% 310K
|
|
| O: 1.78%
H: 19.08%
C: 10.06%
treatment disease
Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
Published: 2022-11-15 (Crawled : 18:00) - biospace.com/
ATNF | $1.91 29.05% 22.51% 310K
|
|
| O: 1.78%
H: 19.08%
C: 10.06%
treatment disease
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
Published: 2023-01-25 (Crawled : 14:00) - globenewswire.com
ATNF | $1.91 29.05% 22.51% 310K
|
|
| O: 15.77%
H: 45.78%
C: 15.53%
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.